SCHEMBL12414489

SCHEMBL12414489

CC(C)C(=O)N1CCNC[C@@H]1C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLD1 Q13393 1/20 0.44
DPP4 P27487 2/20 0.43
PIK3CD O00329 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
CHRNB3 Q05901 1/20 0.35
CHRNA6 Q15825 1/20 0.35
DPP7 Q9UHL4 1/20 0.34
ENPP2 Q13822 1/20 0.33
CHRM5 P08912 1/20 0.32
CHRM3 P20309 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
PAK4 O96013 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25381400 1.00 PLD1 (0.44) PLD1DPP4PIK3CDCHRNB2CHRNA3
SCHEMBL12413694 1.00 PLD1 (0.44) PLD1DPP4PIK3CDCHRNB2CHRNA3
Hydrochloric Acid SCHEMBL28320678 0.98 PLD1 (0.43) PLD1DPP4PIK3CDCHRNB2CHRNA3
Hydrochloric Acid SCHEMBL28320684 0.98 PLD1 (0.43) PLD1DPP4PIK3CDCHRNB2CHRNA3
Hydrochloric Acid SCHEMBL28320677 0.98 PLD1 (0.43) PLD1DPP4PIK3CDCHRNB2CHRNA3
SCHEMBL27110100 0.89 PLD1 (0.37) PLD1DPP4PIK3CDCHRNB2CHRNA3
Trifluoroacetic Acid SCHEMBL28058910 0.89 DPP4 (0.40) PLD1DPP4DPP7
Trifluoroacetic Acid SCHEMBL28320668 0.89 DPP4 (0.40) PLD1DPP4DPP7
Trifluoroacetic Acid SCHEMBL28058919 0.89 DPP4 (0.40) PLD1DPP4DPP7
SCHEMBL12583222 0.87 PLD1 (0.43) PLD1DPP4DPP7ENPP2CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388589-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO LTD (CN) 2025-12-25 US disclosed
US-20240140954-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO., LTD. (CN) 2024-05-02 US disclosed
US-20230278998-A1 Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof 280 BIO, INC. (US) 2023-09-07 US disclosed
WO-2023165571-A1 COMPOUND CONTAINING FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海璎黎药业有限公司 2023-09-07 WO disclosed
US-20230278998-A1 Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof 280 BIO, INC. (US) 2023-09-07 US disclosed
CN-114555593-A 4-substituted indole and indazole sulfonamide derivatives as PARG inhibitors 伊迪亚生物科学有限公司 2022-05-27 CN disclosed
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240140954-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF CYP11B2, SDHA, CYP3A43 PLD1 3558/4885DPP4 1460/4885PIK3CD 370/4885
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO MC2R, REN, CYP11B2 PLD1 1266/4885DPP4 340/4885PIK3CD 1258/4885
US-20250388589-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF CYP4A11, CYP11B1, CYP2D6 PLD1 2939/4885DPP4 1885/4885PIK3CD 2566/4885
US-20230278998-A1 Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof PARG, CYP3A5, CYP11B1 PLD1 4576/4885DPP4 347/4885PIK3CD 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.